Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE:301263)
China · Delayed Price · Currency is CNY 19.83
+0.16 (0.81%)
At close: Aug 20, 2026
SHE:301263 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 648.09 | 674.9 | 721.03 | 760.79 | 783.48 | 653.65 |
Revenue Growth | -3.66% | -6.40% | -5.23% | -2.90% | 19.86% | -7.80% |
Gross Profit Gross Profit Growth | 349.82 | 357.3 | 401.94 | 456.85 | 454.81 | 327.28 |
Operating Income Operating Income Growth | -32.55 | 5.84 | 110.06 | 183.71 | 194.78 | 127.5 |
Net Income Net Income Growth | -4.73 | 28.63 | 108.22 | 160.2 | 174.61 | 120.07 |
Earnings Per Share EPS Growth | -0.01 | 0.06 | 0.22 | 0.32 | 0.37 | 0.31 |
EPS Growth | - | -73.10% | -31.58% | -13.63% | 16.49% | -29.90% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Pharmaceutical Manufacturing Pharmaceutical Manufacturing Growth | 246.76 | 268.79 | 325.02 | 360.85 | 276.53 |
Pharmaceutical Agent Pharmaceutical Agent Growth | 409.41 | 440.52 | 430.29 | 387.75 | 361.71 |
Medical technology services and technology transfer Medical technology services and technology transfer Growth | 17.85 | 10.87 | 4.76 | 34.2 | 15.42 |
Unallocated Other Operating Income Unallocated Other Operating Income Growth | 0.88 | 0.86 | 0.72 | 0.68 | - |
Total Total Growth | 674.9 | 721.03 | 760.79 | 783.48 | 653.65 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 643.4 | 619.93 | 664.06 | 707.45 | 1,047 | 137.63 |
Total Debt Total Debt Growth | 397.14 | 361.59 | 242.65 | 176.27 | 23.16 | 108.9 |
Net Cash (Debt) Net Cash Growth | 246.26 | 258.34 | 421.41 | 531.18 | 1,024 | 28.73 |
Net Cash Growth | -36.22% | -38.70% | -20.67% | -48.14% | 3465.41% | - |
Net Cash Per Share Net Cash Per Share Growth | 0.49 | 0.53 | 0.84 | 1.05 | 2.15 | 0.08 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 81.77 | -12.88 | 89.33 | 93.53 | 148.81 | 120.02 |
Capital Expenditures CapEx Growth | -117.34 | -108.28 | -68.55 | -200.01 | -89.88 | -44.65 |
Free Cash Flow Free Cash Flow Growth | -35.57 | -121.16 | 20.78 | -106.48 | 58.94 | 75.38 |
Free Cash Flow Growth | - | - | - | - | -21.81% | 132.58% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 53.98% | 52.94% | 55.74% | 60.05% | 58.05% | 50.07% |
Operating Margin | -5.02% | 0.86% | 15.26% | 24.15% | 24.86% | 19.51% |
Pretax Margin | -7.99% | -1.21% | 14.64% | 25.28% | 26.47% | 21.04% |
Profit Margin | -0.73% | 4.24% | 15.01% | 21.06% | 22.29% | 18.37% |
FCF Margin | -5.49% | -17.95% | 2.88% | -14.00% | 7.52% | 11.53% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.042 | 0.042 | 0.167 | 0.250 | 0.324 | 0.162 |
Dividend Per Share Growth | -70.00% | -74.98% | -33.32% | -22.86% | 100.06% | - |
Dividend Yield | 0.21% | 0.17% | 1.35% | 1.89% | 2.26% | - |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | 428.80 | 58.66 | 43.37 | 44.00 | - |
Forward PE | - | 66.83 | 25.85 | 22.52 | 28.32 | - |
P/FCF Ratio | - | - | 305.50 | - | 130.35 | - |
PS Ratio | 15.55 | 18.19 | 8.81 | 9.13 | 9.81 | - |